| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter Vestergaard, Leif Mosekild. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. vol 15. issue 2. 2004-04-21. PMID:14625668. |
patients with acromegaly have an excess of gh, and we therefore investigated whether fracture risk was decreased in patients with acromegaly. |
2004-04-21 |
2023-08-12 |
human |
| V Laret, H Valdes Socin, D Betea, M Radermecker, A Stevenaert, A Becker. [Clinical case of the month. Anterior mediastinal mass in a patient with acromegaly]. Revue medicale de Liege. vol 58. issue 12. 2004-04-20. PMID:14978845. |
this can be complicated by the fact that acromegaly can be associated with other tumors (for instance in men-1 disease and carney complex) and because chronic gh hypersecretion can stimulate tumor overgrowth and perhaps tumor formation. |
2004-04-20 |
2023-08-12 |
Not clear |
| Pamela U Freda, Abu T Nuruzzaman, Carlos M Reyes, Robert E Sundeen, Kalmon D Pos. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. The Journal of clinical endocrinology and metabolism. vol 89. issue 2. 2004-03-26. PMID:14764751. |
our initial study in postoperative patients with acromegaly identified a group of patients in remission, as defined by normal igf-i levels, but who had a subtle abnormality of gh suppression after oral glucose. |
2004-03-26 |
2023-08-12 |
human |
| Pamela U Freda, Abu T Nuruzzaman, Carlos M Reyes, Robert E Sundeen, Kalmon D Pos. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. The Journal of clinical endocrinology and metabolism. vol 89. issue 2. 2004-03-26. PMID:14764751. |
normal igf-i level), and of these subjects with acromegaly in remission, 50 had normal nadir gh (<0.14 microg/ml) (group i), and 26 had abnormal nadir gh (>0.14 microg/ml) (group ii). |
2004-03-26 |
2023-08-12 |
human |
| Pamela U Freda, Abu T Nuruzzaman, Carlos M Reyes, Robert E Sundeen, Kalmon D Pos. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. The Journal of clinical endocrinology and metabolism. vol 89. issue 2. 2004-03-26. PMID:14764751. |
we have found that some postoperative subjects with acromegaly in remission with normal igf-i levels have persistently abnormal nadir gh levels after oral glucose that may be accompanied by other evidence of greater gh secretion than postoperative patients with normal gh suppression. |
2004-03-26 |
2023-08-12 |
human |
| Luigi Saccà, Raffaele Napoli, Antonio Cittadin. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clinical endocrinology. vol 59. issue 6. 2004-03-25. PMID:14974906. |
this particular kind of interaction of gh with the cardiovascular system accounts for: (i) the lack of cardiac impairment in short-term acromegaly; (ii) the beneficial effects of gh and igf-i in various models of heart failure; (iii) the protective effect of gh and igf-i against post-infarction ventricular remodelling; (iv) the reversal of endothelial dysfunction in patients with heart failure treated with gh; and (v) the cardiac abnormalities associated with gh deficiency and their correction after gh therapy. |
2004-03-25 |
2023-08-12 |
Not clear |
| Pamela U Fred. Current concepts in the biochemical assessment of the patient with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 4. 2004-03-19. PMID:12914750. |
the diagnosis of acromegaly can be confirmed by documenting an elevated igf-i level in combination with failure of gh to suppress after oral glucose to below 0.3 microg/l, when gh is measured with a highly sensitive and specific assay. |
2004-03-19 |
2023-08-12 |
human |
| Pamela U Fred. Current concepts in the biochemical assessment of the patient with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 4. 2004-03-19. PMID:12914750. |
it is important to recognize that nadir gh levels are >0.3 microg/l in some healthy subjects, so this criterion alone is not diagnostic of acromegaly. |
2004-03-19 |
2023-08-12 |
human |
| Pamela U Fred. Current concepts in the biochemical assessment of the patient with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 4. 2004-03-19. PMID:12914750. |
it is recommended that glucose-suppressed gh levels be interpreted in conjunction with those of igf-i and with consideration of conditions other than acromegaly that can alter them. |
2004-03-19 |
2023-08-12 |
human |
| Pamela U Fred. Current concepts in the biochemical assessment of the patient with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 13. issue 4. 2004-03-19. PMID:12914750. |
with greater assay standardization and the use of igf-i levels along with new rigorous criteria for interpretation of gh suppression during a ogtt we can improve our identification of patients with acromegaly in earlier stages of the disease as well as better recognize residual disease during therapy. |
2004-03-19 |
2023-08-12 |
human |
| Kate McKeage, Susan Cheer, Antona J Wagstaf. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. vol 63. issue 22. 2004-03-10. PMID:14609359. |
in the treatment of acromegaly, octreotide lar effectively controlled the secretion of gh and insulin-like growth factor-1 (igf-1) in about 55-70% of patients (n > 100) who had previously been treated with somatostatin analogues, a similar degree of control to that observed with subcutaneous octreotide and lanreotide slow release (sr). |
2004-03-10 |
2023-08-12 |
Not clear |
| Kate McKeage, Susan Cheer, Antona J Wagstaf. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. vol 63. issue 22. 2004-03-10. PMID:14609359. |
in summary, octreotide lar controls gh and igf-1 secretion in about 55-70% of patients with acromegaly. |
2004-03-10 |
2023-08-12 |
Not clear |
| Aleksandra Modlińska, Anna Babińska, Grzegorz Faran, Krzysztof Sworcza. [Clinical and metabolic effects of recombinant human growth hormone in cardiac insufficiency]. Przeglad lekarski. vol 60. issue 5. 2004-03-08. PMID:14593678. |
on the other hand excessive levels of gh (for example in acromegaly) may induce heart failure too. |
2004-03-08 |
2023-08-12 |
human |
| M Arosio, C L Ronchi, C Gebbia, S Pizzinelli, D Conte, V Cappiello, P Epaminonda, B M Cesana, P Beck-Peccoz, M Peracch. Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly. European journal of endocrinology. vol 150. issue 1. 2004-03-04. PMID:14713276. |
we aimed to verify whether such hormonal responses are retained in acromegaly, a disease characterized by high gh, subnormal ghrelin and abnormal gep hormone levels. |
2004-03-04 |
2023-08-12 |
human |
| Nienke R Biermasz, Alberto M Pereira, Marijke Frölich, Johannes A Romijn, Johannes D Veldhuis, Ferdinand Roelfsem. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American journal of physiology. Endocrinology and metabolism. vol 286. issue 1. 2004-02-12. PMID:14506078. |
octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly gh secretion in acromegaly. |
2004-02-12 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Alberto M Pereira, Marijke Frölich, Johannes A Romijn, Johannes D Veldhuis, Ferdinand Roelfsem. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American journal of physiology. Endocrinology and metabolism. vol 286. issue 1. 2004-02-12. PMID:14506078. |
in summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive gh secretion in acromegaly. |
2004-02-12 |
2023-08-12 |
Not clear |
| F M Swords, P V Carroll, J Kisalu, P J Wood, N F Taylor, J P Monso. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clinical endocrinology. vol 59. issue 5. 2004-02-05. PMID:14616886. |
11 beta hsd1 activity is increased in gh deficiency and inhibited by gh and igf-i in acromegaly. |
2004-02-05 |
2023-08-12 |
Not clear |
| S Grottoli, P Razzore, D Gaia, M Gasperi, M Giusti, A Colao, E Ciccarelli, V Gasco, E Martino, E Ghigo, F Camann. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739738. |
three-hour spontaneous gh secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. |
2004-01-20 |
2023-08-12 |
human |
| S Grottoli, P Razzore, D Gaia, M Gasperi, M Giusti, A Colao, E Ciccarelli, V Gasco, E Martino, E Ghigo, F Camann. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739738. |
the diagnosis of acromegaly, in an appropriate clinical context, usually relies on lack of gh suppression below 1 microg/l during ogtt coupled with elevated igf-i levels. |
2004-01-20 |
2023-08-12 |
human |
| S Grottoli, P Razzore, D Gaia, M Gasperi, M Giusti, A Colao, E Ciccarelli, V Gasco, E Martino, E Ghigo, F Camann. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739738. |
this study shows that a 3-h spontaneous gh profile is as reliable as ogtt in the diagnosis of active acromegaly. |
2004-01-20 |
2023-08-12 |
human |